[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
[2] |
ZHENG R, ZHANG S W, ZENG H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9.
|
[3] |
薛驰, 高鹏, 朱志, 等. 免疫治疗在胃癌的围手术期及转化治疗中的应用和挑战[J]. 中国癌症杂志, 2024, 34(3): 259-267.
doi: 10.19401/j.cnki.1007-3639.2024.03.003
|
[4] |
XUE C, GAO P, ZHU Z, et al. Application and challenge of immunotherapy in perioperative therapy of gastric cancer[J]. China Oncol, 2024, 34(3): 259-267.
|
[5] |
YANG Y, WANG X Y, DUAN C, et al. Clinicopathological characteristics and its association with digestive system tumors of 1 111 patients with Schistosomiasis japonica[J]. Sci Rep, 2023, 13(1): 15115.
|
[6] |
OKABE H, AOYAMA H, MIYAHARA Y, et al. Dorsal approach for advanced gastric cancer invading the transverse mesocolon[J]. Ann Gastroenterol Surg, 2023, 7(4): 678-683.
doi: 10.1002/ags3.12654
pmid: 37416746
|
[7] |
AN W X, BAO L J, WANG C Y, et al. Analysis of related risk factors and prognostic factors of gastric cancer with liver metastasis: a SEER and external validation based study[J]. Int J Gen Med, 2023, 16: 5969-5978.
doi: 10.2147/IJGM.S434952
pmid: 38144441
|
[8] |
DING P A, YANG P G, TIAN Y, et al. The clinical value of further accurate staging of PT2 gastric cancer based on the depth of invasion[J]. Chin J Oncol, 2021, 43(11): 1197-1202.
|
[9] |
FANG C, WANG W, DENG J Y, et al. Proposal and validation of a modified staging system to improve the prognosis predictive performance of the 8th AJCC/UICC pTNM staging system for gastric adenocarcinoma: a multicenter study with external validation[J]. Cancer Commun, 2018, 38(1): 67.
|
[10] |
CHEN A H, CHAN W H, LEE Y H, et al. Routine chest CT for staging of gastric cancer[J]. Br J Surg, 2019, 106(9): 1197-1203.
doi: 10.1002/bjs.11186
pmid: 31210362
|
[11] |
BAI L G, LIU W M, DI S T, et al. Clinical study of CT enhanced scan in preoperative TNM staging of advanced gastric cancer and the effect of misdiagnosis rate[J]. Panminerva Med, 2023, 65(2): 259-260.
|
[12] |
闫文锋, 孙培春, 吴刚, 等. 3D-CT模拟影像描述胃周动脉变异对腹腔镜全胃切除术的指导作用[J]. 中华胃肠外科杂志, 2021, 24(2): 173-178.
|
[13] |
YAN W F, SUN P C, WU G, et al. Application of 3D-CT simulation image in the description of gastric artery variation to guide laparoscopic total gastrectomy[J]. Chin J Gastrointest Surg, 2021, 24(2): 173-178.
|
[14] |
GAI Q, LI X, LI N, et al. Clinical significance of multi-slice spiral CT, MRI combined with gastric contrast-enhanced ultrasonography in the diagnosis of T staging of gastric cancer[J]. Clin Transl Oncol, 2021, 23(10): 2036-2045.
doi: 10.1007/s12094-021-02606-9
pmid: 33830443
|
[15] |
TATSUBAYASHI T, TANIZAWA Y, MIKI Y, et al. Treatment outcomes of hepatectomy for liver metastases of gastric cancer diagnosed using contrast-enhanced magnetic resonance imaging[J]. Gastric Cancer, 2017, 20(2): 387-393.
doi: 10.1007/s10120-016-0611-7
pmid: 27155874
|
[16] |
PARK J Y, JEON T J. Diagnostic evaluation of endoscopic ultrasonography with submucosal saline injection for differentiating between T1a and T1b early gastric cancer[J]. World J Gastroenterol, 2022, 28(46): 6564-6572.
|
[17] |
SHITARA K, FLEITAS T, KAWAKAMI H, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer[J]. ESMO Open, 2024, 9(2): 102226.
|
[18] |
张维汉, 胡建昆. 胃癌腹膜转移诊治现状[J]. 中华胃肠外科杂志, 2021, 24(3): 204-207.
|
[19] |
ZHANG W H, HU J K. Current status of diagnosis and treatment of gastric cancer peritoneal metastasis[J]. Chin J Gastrointest Surg, 2021, 24(3): 204-207.
|
[20] |
NOMA T, TAKAHASHI T, MIYAZAKI Y, et al. Multi-look staging laparoscopy and conversion surgery for gastric cancer with peritoneal metastases[J]. Gan To Kagaku Ryoho, 2019, 46(1): 184-186.
|
[21] |
ZHANG Q, ZHOU Y, SONG L J, et al. China special issue on gastrointestinal tumors-Improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: a multicenter, noninterventional, controlled study[J]. Int J Cancer, 2023, 153(11): 1885-1893.
|
[22] |
CAI Z M, LIN H M, LI Z X, et al. The short- and long-term outcomes of laparoscopic D2 lymphadenectomy plus complete mesogastrium excision for lymph node-negative gastric cancer[J]. Surg Endosc, 2024, 38(2): 1059-1068.
doi: 10.1007/s00464-023-10621-w
pmid: 38082018
|
[23] |
SANDØ A D, GRØNBECH J E, BRINGELAND E A. Does the ypTNM-stage adequately predict long-term survival rates in gastric cancer patients receiving neoadjuvant chemotherapy followed by radical resection?[J]. Acta Oncol, 2023, 62(12): 1846-1853.
|
[24] |
SMYTH E C, NILSSON M, GRABSCH H I, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648.
doi: S0140-6736(20)31288-5
pmid: 32861308
|
[25] |
ZHANG X J, WANG W Q, ZHAO L L, et al. Short-term safety and long-term efficacy of multivisceral resection in pT4b gastric cancer patients without distant metastasis: a 20-year experience in China National Cancer Center[J]. J Cancer, 2022, 13(10): 3113-3120.
doi: 10.7150/jca.75456
pmid: 36046640
|
[26] |
宋武, 何裕隆. 晚期胃癌腹主动脉旁淋巴结转移综合治疗策略[J]. 中国实用外科杂志, 2017, 37(10): 1102-1106.
doi: 10.19538/j.cjps.issn1005-2208.2017.10.09
|
[27] |
SONG W, HE Y L. Comprehensive treatment strategies of advanced gastric cancer with para-aortic lymph node metastasis[J]. Chin J Pract Surg, 2017, 37(10): 1102-1106.
|
[28] |
SASAKO M, SANO T, YAMAMOTO S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer[J]. N Engl J Med, 2008, 359(5): 453-462.
|
[29] |
LI D B, YOU J, WANG S J, et al. Pancreaticoduodenectomy for locally advanced gastric cancer: results from a pooled analysis[J]. Asian J Surg, 2019, 42(3): 477-481.
|
[30] |
SCHIZAS D, GIANNAKODIMOS I, MYLONAS K S, et al. Multivisceral resection for locally advanced gastric cancer: a systematic review and evidence quality assessment[J]. J Clin Med, 2023, 12(23): 7360.
|
[31] |
KUMAGAI K, NUNOBE S, HIKI N, et al. Anatomical position of the pancreas as a risk factor for pancreatic fistula after laparoscopic gastrectomy for gastric cancer[J]. World J Surg, 2023, 47(7): 1744-1751.
doi: 10.1007/s00268-023-06972-z
pmid: 36964789
|
[32] |
CAINAP C, NAGY V, SEICEAN A, et al. Results of third-generation epirubicin/cisplatin/xeloda adjuvant chemotherapy in patients with radically resected gastric cancer[J]. J BUON, 2016, 21(2): 349-359.
pmid: 27273944
|
[33] |
LI N, LI Z, FU Q, et al. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase Ⅱ study[J]. Int J Surg, 2024, 110(4): 2071-2084.
|
[34] |
许永虎, 徐大志. 21世纪以来胃癌治疗进展及未来展望[J]. 中国癌症杂志, 2024, 34(3): 239-249.
doi: 10.19401/j.cnki.1007-3639.2024.03.001
|
[35] |
XU Y H, XU D Z. Progress and prospects of gastric cancer treatment in the 21st century[J]. China Oncol, 2024, 34(3): 239-249.
|
[36] |
XIA L Z, OYANG L, LIN J G, et al. The cancer metabolic reprogramming and immune response[J]. Mol Cancer, 2021, 20(1): 28.
|
[37] |
BOILÈVE J, TOUCHEFEU Y, MATYSIAK-BUDNIK T. Clinical management of gastric cancer treatment regimens[J]. Curr Top Microbiol Immunol, 2023, 444: 279-304.
doi: 10.1007/978-3-031-47331-9_11
pmid: 38231223
|
[38] |
BOKU N, SATOH T, RYU M H, et al. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab[J]. Gastric Cancer, 2021, 24(4): 946-958.
doi: 10.1007/s10120-021-01173-w
pmid: 33743112
|
[39] |
EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
doi: 10.1016/j.ejca.2008.10.026
pmid: 19097774
|
[40] |
TSAGKALIDIS V, BLASZCZYK M B, IN H. Interpretation of tumor response grade following preoperative therapy for gastric cancer: an overview[J]. Cancers, 2023, 15(14): 3662.
|
[41] |
KARABULUT S, DOGAN I, USUL AFSAR C, et al. Does nutritional status affect treatment tolerability, chemotherapy response and survival in metastatic gastric cancer patients? Results of a prospective multicenter study in Turkey[J]. J Oncol Pharm Pract, 2022, 28(1): 127-134.
doi: 10.1177/1078155220987291
pmid: 33435820
|
[42] |
HUANG C M, LIU H, HU Y F, et al. Laparoscopic vs open distal gastrectomy for locally advanced gastric cancer: five-year outcomes from the CLASS-01 randomized clinical trial[J]. JAMA Surg, 2022, 157(1): 9-17.
|
[43] |
KARPEH M S JR. Palliative treatment and the role of surgical resection in gastric cancer[J]. Dig Surg, 2013, 30(2): 174-180.
|
[44] |
李杨, 王权, 叶颖江, 等. 应用减量手术治疗无症状不可切除性晚期胃癌疗效meta分析[J]. 中国实用外科杂志, 2022, 42(1): 80-86.
|
[45] |
LI Y, WANG Q, YE Y J, et al. Meta-analysis of the efficacy of reduction surgery in incurable asymptomatic advanced gastric cancer[J]. Chin J Pract Surg, 2022, 42(1): 80-86.
|
[46] |
汪学非, 周鹏, 唐兆庆. 胃癌外科治疗的新进展及发展趋势[J]. 中国癌症杂志, 2024, 34(3): 250-258.
doi: 10.19401/j.cnki.1007-3639.2024.03.002
|
[47] |
WANG X F, ZHOU P, TANG Z Q. New progress and development trend of surgical treatment for gastric cancer[J]. China Oncol, 2024, 34(3): 250-258.
|
[48] |
WANG X D, CHEN Y, GAO Y S, et al. Predicting gastric cancer outcome from resected lymph node histopathology images using deep learning[J]. Nat Commun, 2021, 12(1): 1637.
|
[49] |
SONG X H, ZHANG W H, KAI-LIU, et al. Prognostic impact of Borrmann classification on advanced gastric cancer: a retrospective cohort from a single institution in western China[J]. World J Surg Oncol, 2020, 18(1): 204.
|